Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring.

Nina ZhouChang LiuXiaoyi GuoYuping XuJifang GongChangsong QiXiaotian ZhangMin YangHua ZhuLin ShenZhi Yang

Published in: European journal of nuclear medicine and molecular imaging (2020)

68Ga-HER2 affibody PET/CT is a feasible method to noninvasively detect the HER2 status in AGC patients and enable early detection with a low dose. Ongoing anti-HER2 therapy did not influence 68Ga-HER2 affibody imaging, which allowed repeated evaluations to monitor the HER2 status after anti-HER2 therapy. This method provides an in vivo understanding of AGC biology that will ultimately help oncologists improve individualized therapy plans.

Keyphrases

pet ct
pet imaging
positron emission tomography
low dose
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
high resolution
prognostic factors
high dose
computed tomography
bone marrow
photodynamic therapy
mesenchymal stem cells
mass spectrometry
smoking cessation